Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6216872 | 1.00 | ALDH1A1 (0.38) | ALDH1A1KDM4EGAAHPGDMAPT | |
| SCHEMBL6213810 | 0.99 | KDM4E (0.38) | ALDH1A1KDM4EGAAHPGDMAPT | |
| SCHEMBL6215039 | 0.97 | KDM4E (0.39) | ALDH1A1KDM4EGAAHPGDMAPT | |
| SCHEMBL6504839 | 0.94 | GAA (0.38) | ALDH1A1KDM4EGAAHPGDMAPT | |
| SCHEMBL6212488 | 0.94 | KDM4E (0.40) | ALDH1A1KDM4EGAAHPGDMAPT | |
| SCHEMBL641797 | 0.91 | KDM4E (0.40) | ALDH1A1KDM4EGAAHPGDMAPT | |
| SCHEMBL641777 | 0.91 | ALDH1A1 (0.45) | ALDH1A1KDM4EGAAHPGDMAPT | |
| SCHEMBL6213958 | 0.90 | GAA (0.37) | ALDH1A1KDM4EGAAHPGDMAPT | |
| SCHEMBL6215748 | 0.88 | GAA (0.37) | ALDH1A1KDM4EGAAHPGDMAPT | |
| SCHEMBL6261168 | 0.88 | GAA (0.39) | ALDH1A1KDM4EGAAHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846735-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2014-09-30 | — | — | US | claimed |
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX, INC. (US) | 2014-03-13 | — | — | US | claimed |
| US-8575205-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2013-11-05 | — | — | US | claimed |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | NITZ THEODORE J (US) | 2012-07-19 | — | — | US | claimed |
| US-8202896-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-06-19 | — | — | US | claimed |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | claimed |
| EP-1545513-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004014316-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-02-19 | — | — | WO | claimed |
| US-8962667-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | Microdose Therapeutix, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8846735-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8575205-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | NITZ THEODORE J (US) | 2012-07-19 | — | — | US | disclosed |
| US-8202896-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1545513-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014316-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | TTPA, HAVCR2, ZC3HAV1 | ALDH1A1 3354/4885KDM4E 4421/4885GAA 1572/4885 |
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | ALDH1A1 3354/4885KDM4E 4421/4885GAA 1572/4885 |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | ALDH1A1 3354/4885KDM4E 4421/4885GAA 1572/4885 |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | ALDH1A1 3354/4885KDM4E 4421/4885GAA 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.